Skip to main content
    L

    Lifecore Biomedical Inc. (LFCR)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $6.42
    -0.01 (-0.08%)

    Market Cap: $243.36M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Lifecore Biomedical Inc. (LFCR) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Lifecore Biomedical (LFCR) to earn -$0.55 per share in the fiscal year ending May 31, 2027, on revenue of $147.73M. Of 5 analysts, 0 rate the stock Buy or Strong Buy, 5 Hold and 0 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending May 31, 2027 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. All 5 rate it Hold.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy00.0%
    Hold5100.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Hold
    Total analysts
    5

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    Fiscal year ending May 31, 2027
    -$0.55
    EPS consensus, revenue $147.73M
    Fiscal year ending Dec 31, 2027
    -$0.88
    EPS consensus, revenue $131.39M
    Next report
    Feb 5, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    May 31, 2027-$0.55-$0.66 to -$0.432$147.73M$146.06M to $150.33M4
    Dec 31, 2027-$0.88-$1.08 to -$0.764$131.39M$130.30M to $134.37M4

    Quarterly Estimates

    The EPS consensus falls from -$0.10 for the quarter ending Dec 31, 2026 to -$0.28 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.10-$0.14 to -$0.054$37.89M$37.89M to $37.89M1
    Mar 31, 2027-$0.28-$0.30 to -$0.273$27.10M$25.39M to $29.57M3

    Estimate Revisions

    Across the 4 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending May 31, 202701
    Fiscal year ending Dec 31, 202700
    Quarter ending Dec 31, 202600
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending May 31, 2027 has worsened from -$0.43.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending May 31, 2027-$0.55-$0.45-$0.45-$0.45-$0.43N/A
    Fiscal year ending Dec 31, 2027-$0.88-$0.89-$0.88-$0.88-$0.99N/A
    Quarter ending Dec 31, 2026-$0.10-$0.09-$0.10-$0.10-$0.18N/A
    Quarter ending Mar 31, 2027-$0.28-$0.29-$0.28-$0.28-$0.30N/A

    Frequently Asked Questions About LFCR

    What is the LFCR stock forecast?

    Consensus analyst estimates put Lifecore Biomedical's EPS at -$0.55 for the fiscal year ending May 31, 2027, on revenue of $147.73M. The consensus rating from 5 analysts is Hold.

    How do analysts rate LFCR stock?

    Of 5 analysts covering Lifecore Biomedical, 0 rate it Strong Buy, 0 Buy, 5 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from LFCR next year?

    For the fiscal year ending May 31, 2027, the consensus EPS estimate is -$0.55, with estimates from -$0.66 to -$0.43 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.88, with estimates from -$1.08 to -$0.76 from 4 analysts.

    What revenue do analysts expect from Lifecore Biomedical next year?

    For the fiscal year ending May 31, 2027, the consensus revenue estimate is $147.73M, with estimates from $146.06M to $150.33M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $131.39M, with estimates from $130.30M to $134.37M.

    How many analysts cover LFCR?

    5 analysts rate Lifecore Biomedical stock, and 2 analysts estimate its EPS for the fiscal year ending May 31, 2027.